Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review

The document outlined a protocol for a scoping review to evaluate the evidence on drugs targeting the JAK/STAT pathway for treating dermatological diseases such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and melanoma. Despite the growing evidence of JAK/STAT inhibitors' potential in dermatology, none had been approved for skin disease treatment at the time. The review aimed to systematically gather and analyze existing studies using a five-stage methodology from the Joanna Briggs Institute, with results to be reported following the PRISMA-ScR guidelines. The findings were intended for dissemination through peer-reviewed publications and conference presentations.